Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.17016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utility of T2 cell biomarkers to predict outcomes and treatment response in children with asthma.
J Allergy Clin Immunol
July 2024
Department of Biomedical Engineering, University of Virginia School of Medicine, Charlottesville, Va.
Role of biologics in severe food allergy.
Curr Opin Allergy Clin Immunol
June 2024
Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Purpose Of Review: This review examine the dynamic landscape of food allergy treatment within the context of emerging biologics. Our purpose is to comprehensively evaluate the potential benefits, challenges, and transformative impact associated with the utilization of biologics in comparison to conventional therapeutic modalities.
Recent Findings: This document synthesizes recent scientific investigations to various biologics, such as omalizumab, ligelizumab, dupilumab, and tezepelumab, providing a nuanced understanding of their roles in oral immunotherapy, rapid desensitization, and overall food allergy management.
The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs.
Int J Mol Sci
January 2024
Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy.
Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms involved in the pathogenesis of EoE and biologics, in particular monoclonal antibodies (mAbs), targeting these pathways are needed. Currently, the most relevant is dupilumab, which interferes with both interleukin (IL)-4 and IL-13 pathways by binding IL-4 receptor α, and is the only mAb approved by the European Medicine Agency and US Food and Drug Administration for the treatment of EoE.
View Article and Find Full Text PDFDupilumab: a new frontier for chronic urticaria. A case series and review of the literature.
Int J Dermatol
March 2024
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Diagnostic challenges and updated therapeutic strategies of Kimura's disease: A case report successfully treated by dupilumab and review.
Medicine (Baltimore)
November 2023
Claude Bernard Lyon 1 University, Lyon, France.
Rationale: Kimura's disease (KD) is a rare and chronic eosinophilic related-disease, characterized by subcutaneous tissue masses, regional enlarged lymph nodes, hypereosinophilia and elevated serum IgE. KD usually affects young adults in the Asian population. In Western countries, the clinical and biological presentation of KD is often unknown, delaying the diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!